Drugs / GSK1995057
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01587807 | Mar → Nov 2012 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01476046 | Mar 2011 → Jun 2012 | respiratory system disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1995057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01476046 ↗ |
| Action | Inhibit | “We developed a potent and selective antagonist of TNFR1 (GSK1995057) using a novel domain antibody (dAb) therapeutic” PMID 29382797 ↗ Jan 20181“Tumor necrosis factor receptor R1 inhibitor” CHEMBL2109590 ↗ |
| Modality | Protein / enzyme biologic | “GSK1995057 is a fully human, single domain antibody directed against the TNFR1 receptor.” NCT01587807 ↗ |
| Route | Intravenous | “single and repeat intravenously infused doses” NCT01476046 ↗ |
| Target | TNFRSF1A | “Tumor necrosis factor receptor R1 inhibitor” CHEMBL2109590 ↗ |